Compare BWBBP & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWBBP | VANI |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 119.0M |
| IPO Year | 2018 | 2014 |
| Metric | BWBBP | VANI |
|---|---|---|
| Price | $19.51 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 1.7K | ★ 180.5K |
| Earning Date | N/A | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.66 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.76 | $0.92 |
| 52 Week High | $21.20 | $1.92 |
| Indicator | BWBBP | VANI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.74 |
| Support Level | N/A | $1.24 |
| Resistance Level | N/A | $1.25 |
| Average True Range (ATR) | 0.00 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 53.00 |
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.